[Company Profile] Stentys
Medical device company Stentys seeks to correct the problem of poor apposition with its self-expanding stent technology.
Articles by vanderson
Bioguard Wound Dressings Beat Swine Flu In Independent Study
Derma Sciences, a developer of wound care products, announced that its Bioguard Barrier Dressings effectively safeguarded against the H1N1 “swine flu” virus in an independent laboratory study.
Celgene Acquires Gloucester In $340M Deal
Biopharmaceutical company Celgene is plumping up its oncology pipeline with its latest acquisition.
Vertex to Sell 1.5 Million Shares
Vertex Pharmaceuticals has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C.
Hope for Epilepsy Patients, But Treatment Gap Exists Worldwide
An exciting discovery may change the way epilepsy is treated, but if current evidence is any indication, getting the treatment to patients will be a challenge.
Potential Hepatitis C Breakthrough for Santaris
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
FDA Approves Treatment for Rare Swelling Disease
Biopharmaceutical company Dyax Corporation has received regulatory approval to market its drug ecallantide (Kalbitor) for a rare genetic disorder called hereditary angioedema (HAE).
Provectus Reports Positive Preliminary Data for Dermatology Drug
Patients with psoriasis demonstrated 79% improvement in the Psoriasis Scoring Index after four weeks of daily treatment with PH-10.
Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
Cancer Vaccines: Investing Opportunities Beyond Dendreon
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.